Dennis Keefe

Dennis Keefe is the Chief Scientific Officer of Prothelia. Dennis brings over 15 years’ experience in developing drugs for rare diseases of high unmet medical need. Prior to joining Prothelia, Dr. Keefe held leadership positions at Stealth Biotherapeutics and Shire Human Genetic Therapies, leading cross functional teams focused on the preclinical and nonclinical development of innovative therapies for the treatment of neurodegenerative and neuromuscular disease, including Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Friedreich’s Ataxia and Huntington’s Disease. Dr. Keefe received his PhD in Immunology from Tufts University and completed his post-doctoral fellowship at Harvard Medical School. He also holds an MBA from the D’Amore-McKim School of Business at Northeastern University.